We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Novel Classification System Identifies Prostate Cancer Patients Who May Benefit from Combined Immune and Radiation Therapies

By LabMedica International staff writers
Posted on 22 Dec 2020
A novel classification system is expected to aid in the subtyping of aggressive prostate cancers in patients who may benefit from combined immune and radiation therapies.

Prostate cancer is graded from 1 to 5 based on how aggressive it is, with 5 being the most aggressive. More...
Patients with 4/5 grade cancers are at the highest risk of poor outcomes or death from the disease. However, currently there are no immunologic or genomic indicators for determination of the best course of treatment for this group of patients.

Investigators at the Moffitt Cancer Center & Research Institute (Tampa, FL, USA) employed two classifiers – the tumor immune content score (ICS) and the Decipher genomic classifier - to assess whether transcriptomic interactions between the two classifiers could identify the most lethal subsets of grade 4/5 prostate cancers. The ICS was derived from the mean expression of 264 immune cell-specific genes, while the Decipher score was based on 22 RNA biomarkers that predicted the probability that a cancer would spread.

For the current study, the investigators analyzed data from 8,071 prostate cancer patient samples of any disease grade (6,071 prostatectomy and 2,000 treatment naïve) in the Decipher Genomics Resource Information Database (GRID) registry. Each patient sample also received an ICS rating.

The samples were separated into four distinct immuno/genomic subsets based on the results: ICS high/Decipher high, ICS low/Decipher high, ICS high/Decipher low, and ICS low/Decipher low.

Results of the analyses revealed that approximately 25% of all grade 4/5 patient samples were in the ICS high/Decipher high subset. The ICS high/Decipher high subtype was associated with increased sensitivity to radiotherapy. Additionally, the ICS high/Decipher high subtype had a significantly higher risk of distant metastasis as compared with the ICS low/Decipher low subtype.

The creation of these novel immuno/genomic subtypes established a very strong synergistic interaction between ICS and Decipher in identifying grade 4/5 prostate cancer patients who are likely to experience the most lethal outcomes.

"Our results will aid in the subtyping of aggressive prostate cancer patients who may benefit from combined immune-radiotherapy modalities," said first author Dr. Kosj Yamoah, director of cancer disparities research at the Moffitt Cancer Center.

The study was published in the December 7, 2020, online edition of the journal European Urology.

Related Links:
Moffitt Cancer Center & Research Institute


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.